Press Releases

Press Releases

Date Title & Summary Additional Formats
01/04/18
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a
11/28/17
Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections
Topline Data Expected in First Quarter 2018 SAN DIEGO , Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the STRIVE trial, a Phase 2
11/13/17
Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
Employee feedback places company among top 10 in San Diego Metro Area SAN DIEGO , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a 2017 Top
11/08/17
Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Conference call and webcast today at 1:05 p.m. PST/4:05 p.m. EST SAN DIEGO , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended
11/01/17
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after the close of U.S.
10/19/17
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
SAN DIEGO , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share.
09/25/17
Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
Data Highlight Advantages of CD101 in Difficult-to-Treat Infections SAN DIEGO , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies
09/18/17
Cidara Therapeutics to Present at Two Upcoming Conferences
SAN DIEGO , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
09/07/17
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
SAN DIEGO , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., the company’s president and chief executive officer, will participate in a keynote
09/06/17
T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
Exclusive pricing program designed to drive uptake of T2 Biosystems' products and accelerate enrollment in Cidara's CD101 trials, targeting deadly sepsis-causing pathogen Candida LEXINGTON, Mass. and SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.